Objective-Oxidative stress plays a critical role in the development of abdominal aortic aneurysm (AAA). Intermedin (IMD) is a regulator of oxidative stress. Here, we investigated whether IMD reduces AAA by inhibiting oxidative stress. Approach and Results-In angiotensin II-induced ApoE −/− mouse and CaCl 2 -induced C57BL/6J mouse model of AAA, IMD 1−53 significantly reduced the incidence of AAA and maximal aortic diameter. Ultrasonography, hematoxylin, and eosin staining and Verhoeff-van Gieson staining showed that IMD 1−53 significantly decreased the enlarged aortas and elastic lamina degradation induced by angiotensin II or CaCl 2 . Mechanistically, IMD 1−53 attenuated oxidative stress, inflammation, vascular smooth muscle cell apoptosis, and matrix metalloproteinase activation. IMD 1−53 inhibited the activation of redox-sensitive signaling pathways, decreased the mRNA and protein expression of nicotinamide adenine dinucleotide phosphate oxidase subunits, and reduced the activity of nicotinamide adenine dinucleotide phosphate oxidase in AAA mice. Expression of Nox4 was upregulated in human AAA segments and in angiotensin II-treated mouse aortas and was markedly decreased by IMD 1−53 . In vitro, vascular smooth muscle cells with small-interfering RNA knockdown of IMD showed significantly increased angiotensin II-induced reactive oxygen species, and small-interfering RNA knockdown of Nox4 markedly inhibited the reactive oxygen species. IMD knockdown further increased the apoptosis of vascular smooth muscle cells and inflammation, which was reversed by Nox4 knockdown. Preincubation with IMD 17−47 and protein kinase A inhibitor H89 inhibited the effect of IMD 1-53 , reducing Nox4 protein levels. Conclusions-IMD 1−53 could have a protective effect on AAA by inhibiting oxidative stress. (Arterioscler Thromb Vasc Biol.
A bdominal aortic aneurysm (AAA), a progressive aortic dilation, is a common vascular disease associated with high mortality. 1 Although conventional treatments including surgery or percutaneous intervention are performed in highrisk patients, effective medical therapies for AAA have not been developed. 2 The hallmark pathological features of AAA are typified by intense oxidative stress, inflammation, matrix degradation, and apoptosis of vascular smooth muscle cells (VSMCs). 3 Reactive oxygen species (ROS) are thought to be a common link between inflammation, matrix degradation, and VSMC apoptosis, 4, 5 so reducing ROS may be a therapeutic target of AAA. In animal models of AAA, genetic and pharmacological inhibition of ROS suppressed aneurysm formation. [6] [7] [8] A major source of ROS in vascular tissue is the membrane-bound nicotinamide vadenine dinucleotide phosphate (NADPH) oxidase, which contains transmembrane subunits such as Nox1-5, Duox1 and Duox2, and p22phox and cytosolic subunits such as p47phox, p67phox, Rac1, and optionally p40phox (for Nox2) or the respective homologs of p47phox and p67phox, NOXO1 and NOXA1 (for Nox1). These subunits assemble to form a functional oxidase. 9 NADPH oxidase activity was markedly upregulated in human aneurysmal aortas. 10 Inhibition of NADPH oxidase attenuated AAA formation, which suggests that NADPH oxidase plays a critical role in AAA formation. 6, 11 Nox1 and Nox4 are the 2 Nox isoforms expressed in VSMCs, 12 where ROS are mainly generated in AAA. 8 Nox4 has been shown to produce hydrogen peroxide (H 2 O 2 ), which induced apoptosis in VSMCs. 12 Nox4-mediated oxidative stress may participate in the pathogenesis of AAA.
Paracrine/autocrine factors are involved in maintaining circulatory homeostasis and mediating the pathogenesis of cardiovascular diseases. 8, 13 Some of these factors such as adrenomedullin (ADM) can antagonize oxidative stress and have properties of anti-inflammation, suppression of proliferation, and migration of VSMCs as well as promotion of growth and reparation of endothelium. 13 Thus, investigation of endogenous peptides may help reveal new mechanisms and therapeutic strategies for AAA.
Intermedin (IMD), also known as ADM-2, is a peptide that belongs to the calcitonin/calcitonin gene-related peptide (CGRP) family, which includes calcitonin, CGRP, amylin, and ADM. 14 IMD is produced from various cells of the cardiovasculature, including vascular endothelial cells, VSMCs, cardiomyocytes and fibroblasts, [15] [16] [17] and even macrophages. 18 Human IMD gene encodes a prepropeptide of 148 amino acids with a signal peptide for secretion at the N terminus. IMD can be generated from prepro-IMD by proteolytic cleavage at Arg93-Arg94. IMD elicits its biological actions via nonselective interaction with different combinations of calcitonin receptor-like receptor (CRLR) and the 3 receptor activity-modifying proteins (RAMPs). 15 The main pharmacological effects of IMD are attributed to the activation of cAMP/protein kinase A (PKA) signaling. 19 IMD could ameliorate vascular and renal injury by inhibiting oxidative stress in DOCA-salt hypertensive rats 20 and had an antioxidant effect on myocardial injury induced by ischemia/reperfusion in vivo. 21 These data suggest that IMD is an endogenous cardiovascular-protective peptide that protects the cardiovascular system against oxidative damage, a potential risk factor for AAA. However, whether IMD reduces the formation of AAA by inhibiting oxidative stress is unclear. In this study, we investigated the role and possible mechanism of IMD in an angiotensin II (Ang II)-or CaCl 2induced AAA mouse model.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

IMD 1−53 Prevented the Development of AAA
To determine whether IMD is altered in the formation and progression of AAA, we first investigated IMD expression in AAA tissues. IMD immunoreactivity was significantly increased in the human aneurysmal aortas ( Figure ⅠA in the online-only Data Supplement). Then, we further clarified this role in Ang II-induced ApoE −/− mice model of AAA. As Figure Ⅰ in the online-only Data Supplement showed, treatment with Ang II for 4 weeks promoted AAA formation in ApoE −/− mice (Figure ⅠB through IE and Table Ⅱ in the online-only Data Supplement). Plasma IMD content was higher by 53% (P<0.01) in Ang II-treated than control mice ( Figure 1A ). Similar to human AAA, IMD level was greater in the tunica media of Ang II-treated AAA than control aortas ( Figure 1D ), whereas the mRNA level of IMD in vascular tissue was lower ( Figure 1B) . The mRNA levels of CRLR and RAMP1 and 3 were higher by 4.7-, 3.23-, and 4.88fold (all P<0.05), respectively, in Ang II-treated AAA than control aortas, but RAMP2 mRNA expression was lower by 76.1% (P<0.05; Figure 1C ). The protein levels of CRLR and RAMP2 and 3 were higher by 117%, 27.8%, and 105.4% (all P<0.05), respectively, in Ang II-treated AAA than control aortas, but RAMP1 protein expression was lower by 43.6% (P<0.05; Figure 1E and 1F).
We further measured IMD and its receptor levels in CaCl 2induced AAA. CaCl 2 treatment led to gradual aortic dilatation associated with elastin fragmentation ( Figure ⅡA and IIB in the online-only Data Supplement). Plasma IMD content was decreased at day 7, then recovered, with no difference at later times when compared with day 0 ( Figure ⅡC Next, we explored whether IMD has a protective role in AAA development. IMD 1−53 treatment decreased the incidence of AAA in Ang II-infused ApoE −/− mice by 34.9% when compared with Ang II alone ( Figure 1G and 1H). As expected, Ang II infusion increased systolic blood pressure in ApoE −/− mice, whereas there was no significant change of systolic blood pressure in IMD 1−53 -supplemented mice ( Figure 1I ). All animals showed severe hyperlipidemia, as expected in ApoE −/− mice; however, Ang II infusion did not affect lipid levels ( Table Ⅲ in the online-only Data Supplement). Plasma levels of total plasma total cholesterol, triglyceride, and low-density lipoprotein cholesterol were lower, by 22.6%, 29.3%, and 24.1% (all P<0.05), for IMD 1−53 -treated than IMD 1−53 -untreated Ang II-infused ApoE −/− mice and that of high-density lipoprotein cholesterol was higher by 24.7% (P<0.05, Table Ⅲ in the online-only Data Supplement). Maximal aortic diameter was lower, by 29.2% (P<0.05), for IMD 1−53 -treated than untreated Ang II-infused ApoE −/− mice ( Figure 1L ). Ang II markedly increased tissue mass and aortic size of both the lumen and wall of Ang II-infused ApoE −/− mouse aortas, which were inhibited by IMD 1−53 ( Figure 1J and 1K ). On Verhoeff-Van Gieson staining, the elastic lamina was frequently disrupted and degraded in Ang II-infused ApoE −/− mice, which were reversed by IMD 1−53 ( Figure 1M Figure  1N ). Then, we further confirmed this effect in CaCl 2 -induced AAA in mice. IMD 1−53 treatment significantly reduced the enlargement of arteries ( Figure ⅢA 
IMD 1−53 Attenuated Oxidative Stress In Vivo and In Vitro
Increased amounts of ROS are considered as key mediators of AAA formation. 10 We evaluated the effect of IMD on ROS generation in vivo. Ang II or CaCl 2 increased the level of ROS, which was decreased by IMD 1−53 ( Figure 2A ; Figure ⅢF in the online-only Data Supplement). In vitro, ROS production was increased in VSMCs in response to Ang II for 4 hours, whereas IMD or the antioxidant N-acetylcysteine (NAC) both reduced the level of ROS induced by Ang II ( Figure 2B ). Infusion with Ang II increased the level of malondialdehyde in aortic tissue, which was reduced by IMD 1−53 ( Figure 2C ). NADPH oxidase, a primary source of ROS in vascular tissues, plays a critical role in the pathogenesis of AAA. 10 IMD 1−53 abrogated NADPH oxidase activity in aortas of AAA mice ( Figure 2D ). Consistently, IMD 1-53 treatment significantly decreased the mRNA levels of p47phox, Nox2, and Nox4 in Ang II-or CaCl 2 -induced aneurysmal aortas, with no difference in Nox1 level ( Figure 2E and 2F). In addition, we found Nox2 and Nox4 protein levels were increased in aortas of AAA mice with Ang II induction, which were blocked with IMD 1-53 treatment ( Figure 2G and 2H).
IMD 1−53 Inhibited Inflammation, VSMC Apoptosis, and Activation of Redox-Sensitive Signaling Pathways by Attenuating Oxidative Stress In Vivo and In Vitro
One mechanism of oxidative stress contributing to vascular disease is by enhancing vascular leukocyte infiltration and extensive vascular inflammation, a key event in AAA formation. 8 In this study, IMD 1−53 downregulated the mRNA expression of monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), and interferon-γ in Ang II-or CaCl 2 -induced aneurysmal aortas ( Figure 3A and 3B ). In addition, we observed marked infiltration of CD68-positive macrophages in the aortic medium and adventitia after CaCl 2 treatment, which was reduced with IMD 1−53 infusion ( Figure ⅢG in the online-only Data Supplement). Then, we studied MCP-1 expression in the aortic wall because of their known role in macrophage migration and AAA formation. 22 MCP-1 was highly expressed in tunica media or adventitia, and its level was reduced by IMD 1−53 ( Figure ⅢH in the online-only Data Supplement). To ascertain whether IMD attenuated vascular inflammation by inhibiting oxidative stress, NAC was used as a positive control in vitro. Ang II treatment induced the protein expression of IL-6, MCP-1, tumor necrosis factor-α, and nuclear factor-κB in rat aortic fibroblasts, whereas pretreatment with IMD 1−53 or NAC effectively blocked their induction ( Figure ⅣA in the online-only Data Supplement). VSMC apoptosis in the aortic media contributes to aortic wall damage and promotes AAA development 1 ; thus, inhibition of apoptosis may retard AAA progression. The amount of bcl2 and bax are involved in the regulation of apoptosis, and p53 was reported to be upregulated in human AAA aorta. 23 We found that IMD 1−53 blunted the protein expression of p53 and bax but increased that of bcl2 ( Figure  3C ROS plays a key role in regulation of inflammation, induction of VSMC apoptosis, and activation of MMPs in the pathogenesis of AAA by activating redox signaling pathways. 5 To dissect the possible mechanism by which IMD 1−53 attenuates AAA, we investigated mitogen-activated protein kinase (MAPK) signaling, known to be involved in inducing cell apoptosis, inflammation, and MMP activation. 24 The phosphorylation of c-Jun N-terminal kinase (JNK) and extracellular-regulated protein kinase (ERK) was increased in aortas of Ang II-treated mice and was abrogated by IMD 1−53 ( Figure 3E and 3F), with no difference in the activation of p38 ( Figure 3G ). We further confirmed the phosphorylation of JNK and ERK1/2 in rat VSMCs. The phosphorylation of JNK and ERK was decreased by IMD 1−53 treatment when compared with Ang II alone (JNK: 15, 30, and 60 minutes, P<0.05. ERK: 15 and 30 minutes, P<0.05; 60 minutes, P<0.01; Figure  IVD in the online-only Data Supplement). Ang II can activate MAPK. 25 To determine the specificity of IMD inhibition on ROS activating redox-sensitive signaling pathways, we mea- 
IMD 1−53 Attenuated Inflammation and VSMC Apoptosis by Inhibiting NADPH Oxidase In Vivo
To determine whether IMD reduced ROS production by inhibiting NADPH oxidase, we used apocynin, an NADPH oxidase inhibitor, as a positive control in vivo. IMD significantly reduced AAA formation induced by Ang II ( Figure ⅤA NADPH oxidase contributes to ROS production, then leading to vascular diseases by enhancing vascular leukocyte infiltration and VSMC apoptosis, key events in AAA formation in this experimental model. 26 We, therefore, investigated whether IMD could attenuate inflammation and apoptosis by inhibiting NADPH oxidase. Dihydroethidium and nitrotyrosine staining showed that IMD 1−53 or apocynin supplementation attenuated ROS generation induced by Ang II in abdominal aortas ( Figure  ⅤG in the online-only Data Supplement; Figure 4A ), which was further confirmed in human aortic SMCs ( Figure ⅤH and VI in the online-only Data Supplement). IMD 1−53 or apocynin treatment both reduced vascular wall production of IL-6 and MCP-1 stimulated by Ang II (Figure 4B and 4C) . Moreover, the amount of terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive cells was greatly decreased in the aortic media with IMD 1−53 or apocynin treatment when compared with saline treatment ( Figure 4D ). Immunostaining of α-SMA revealed that IMD 1−53 or apocynin treatment preserved medial smooth muscle cells ( Figure 4E ).
IMD 1−53 Attenuated VSMC Apoptosis and Inflammation by Inhibiting Nox4 In Vitro
We further confirmed the role of NADPH oxidase in the antioxidant effect of IMD in vitro. Ang II treatment upregulated the protein expression of bax but decreased that of bcl2 in VSMCs, which was reversed by pretreatment with IMD 1−53 or diphenyleneiodonium ( Figure ⅥA and VIB in the online-only Data Supplement). VSMC apoptosis analysis revealed a similar pattern ( Figure ⅥC in the online-only Data Supplement). Nox1 and Nox4 are 2 Nox homologs mainly expressed in VSMCs that contribute greatly to ROS generation in vessels. 12 The mRNA expression of Nox1 did not differ between the AAA and saline group (Figure 2E and 2F ). So we inferred that Nox4 might play an important role in ROS production in AAA. Nox4 expression was higher in human AAA than in normal aortas; Ang II increased the expression of Nox4 in aortas of AAA mice, which was reversed by IMD 1 ⅦA and VIIB in the online-only Data Supplement). To further explore the potential role of Nox4 in the IMD antioxidant effect on apoptosis and inflammation, we knocked down Nox4 and IMD by small-interfering RNA (siRNA; Figure 5A through 5C). IMD silencing increased Ang II-evoked ROS production in VSMCs, and Nox4 silencing inhibited ROS generation in IMD-silenced VSMCs ( Figure 5D ). Similarly, IMD silencing further increased the Ang II-increased protein expression of bax, p53, and cleaved-caspase3 but further decreased the Ang II-decreased bcl2 protein expression, which was reversed by Nox4 silencing (Figure 5E through 5H). VSMC apoptosis by Hoechst staining analysis revealed a similar pattern ( Figure 5I ). Also, pretreatment with IMD 1−53 or diphenyleneiodonium could reverse the Ang II-upregulated protein expression of IL-6, MCP-1, and nuclear factor-κB in adventitial fibroblasts ( Figure ⅥD and VIE in the online-only Data Supplement). In addition, cultured supernatant from Ang II-stimulated VSMCs with siRNA IMD further increased the protein expression of IL-6, MCP-1, and nuclear factor-κB upregulated by cultured supernatant from Ang II-stimulated VSMCs, which was markedly reversed in fibroblasts treated with cultured supernatant from Ang II-stimulated VSMCs with siRNA IMD that were treated with siRNA Nox4 (Figure 5J ).
IMD 1−53 Inhibited NADPH Oxidase Via a cAMP/PKA Pathway
IMD exerts its biological effects by activating signaling pathways such as cAMP/PKA, PI3K/Akt, or ERK1/2 by binding to its receptors, the CRLR/RAMP system. 19, 21 Nox4 protein levels were increased in Ang II-treated VSMCs and were reversed by IMD 1−53 treatment; preincubation with IMD 17−47 but not ADM 22−52 and CGRP 8−37 inhibited the effect of IMD 1-53 on levels of Nox4 ( Figure 6A) . To investigate the signaling pathway by which IMD 1-53 inhibits Ang II-stimulated Nox4 expression in VSMCs, cells were preincubated with the PI3K inhibitor LY294002, PKA inhibitor H89, or ERK signaling inhibitor PD98059. Preincubation with H89 reversed the effect of IMD 1-53 inhibiting Ang II-induced Nox4 protein levels induced by Ang II, but LY294002 or PD98059 had no effect ( Figure 6B ).
Discussion
In this study, we showed that endogenous expression of IMD and its receptor was significantly changed in the aortas of Ang II-or CaCl 2 -induced AAA mice, and exogenous IMD 1−53 prevented the development of AAA through its antioxidant effect. The antioxidant action of IMD might be mediated by inhibiting Nox4 via activating cAMP/PKA signaling by binding its receptors, CRLR/RAMPs, thus protecting mice against developing characteristic features of aneurysm, including inflammation, disruption of elastic fibers, and loss of VSMCs. IMD might be an effective therapeutic target for AAA treatment in clinical practice.
Two AAA animal models were used in this study: ApoE −/− male mice infused with Ang II for 4 weeks and perivascular application of CaCl 2 onto the infrarenal aorta of mice. Both models show evidence of aortic elastin degradation, inflammatory cell infiltration, oxidative stress, and high aortic concentrations of MMPs. 27 Ang II-induced AAA, associated with atherosclerosis, most commonly arise as an acute dissection with associated intramural thrombus. 28 CaCl 2 -induced AAA formation mainly relies on the disruption of the elastic network within the media by calcium precipitations and the activation of the inflammatory response. 29 We first examined changes in IMD and its receptor in the Ang II-or CaCl 2 -induced AAA mice model. Consistent with the results of IMD in cardiac hypertrophy 30 or ADM in patients with arteriosclerosis, 13 we found a marked increase in IMD protein level in Ang II-induced AAA mouse aortas and plasma. Compensatory upregulation of endogenous IMD in vessels may play a protective role in AAA. 30 Furthermore, the upregulated mRNA and protein levels of CRLR/RAMP3 in AAA mouse aortas indicated that the special receptor complexes of IMD/CRLR/RAMP3 were enhanced in the presence of Ang II-induced AAA. In CaCl 2 -induced AAA, the protein level of IMD was upregulated in aortas but was reduced in plasma in the early stage of AAA. The inconsistent trend in aortic tissue and plasma may be attributed to the acceleration of degradation and secretion disorder of IMD. The mRNA levels of its receptors CRLR and RAMPs were all increased at 7 days after the periaortic incubation of CaCl 2 , then recovered to a normal level at later times. The expression profile of IMD and its receptors varies by disease state, and stage of disease, 17, 30 which may explain the different changes in expression of IMD and its receptors in the 2 AAA models or at different stages of CaCl 2 -induced AAA. In all, the changes of IMD level and its receptor in the systemic imbalance and local damage-induced AAA suggest that this peptide acts as a regulatory autocrine or paracrine modulator of AAA and may have a protective role in AAA. Growing evidence affirmed that IMD is a potent endogenous cardiorenal-protective substance. 19 We found that IMD prevented the progression of AAA induced by Ang II or CaCl 2 . MMPs are generally considered putative therapeutic targets in the prevention of AAA. 3 In this study, we found that IMDtreated mice showed decreased MMP activity, which prevented the destruction of medial elastin in the 2 AAA models. IMD can elicit its cardiovascular-protective effect by inhibiting oxidative stress, and a variety of medications and interventions have successfully suppressed experimental aneurysm formation via a ROS-based mechanism. 31, 32 Our results demonstrated that IMD treatment attenuated ROS generation and lipid peroxidation products in aortas of Ang II-induced mice with AAA, which was confirmed in the CaCl 2 -induced AAA model. Our results agree with earlier reports that in situ measurements of ROS generation and MMP activity were greatest in medial cells that stained for α-SMA, 8 so ROS were mainly from VSMCs. We further confirmed this result in cultured VSMCs that IMD decreased ROS generation stimulated by Ang II. Previous studies have reported that IMD could ameliorate vascular and renal injury by inhibiting oxidative stress 20 and showed antioxidant effects on myocardial injury, 21 which strongly supports the antioxidant effect of IMD in this study. In light of the evidence that antioxidants such as vitamin E 33 , quercetin, 34 or overexpression of catalase 35 could prevent experimental AAA formation, IMD may prevent AAA via its antioxidant effect, which may explain, in part, the inhibition of MMP activity by IMD.
In our present study, IMD infusion significantly improved lipid profile in Ang II-induced AAA model, which was consistent with previous study that IMD altered lipid profiles and ameliorated the development of atherogenic diet-induced atherosclerosis in ApoE −/− mice. 36 The protective effect of IMD on AAA might be partly through beneficially modifying the circulating lipid profile. As to the model of Ang II-induced AAA in ApoE −/− mice, Ang II was the main factor that accelerated the formation of AAA by promoting vascular inflammation, oxidative stress, atherosclerosis, and increased vascular stiffness without altering serum cholesterol concentrations or distribution of lipoprotein cholesterol. 37 The antioxidant effect of IMD on inhibiting Ang II-induced apoptosis, inflammation, and MMPs activation also contributed to its protective effect on AAA. The study on CaCl 2 -induced AAA (a model without hyperlipidemia) further confirm the antioxidant effect of IMD on inhibiting AAA development. Further study may be needed to confirm the key mechanism of the protective effect of IMD on AAA.
We further found that IMD inhibited recruitment of inflammatory CD68-positive macrophages in the adventitia, which agrees with earlier reports that inflammatory cells, especially macrophages, were mainly observed in the tunica adventitia of human aneurismal tissues. The pathogenesis of AAA is possibly initiated by macrophage recruitment into the adventitia, then presentation in the media. 22 Various proinflammatory cytokines are secreted from the vessel cells to induce more inflammatory cells. 38 In the 2 AAA models, IMD successfully suppressed the protein expression of proinflammatory cytokines IL-6 and MCP-1. 8 Furthermore, we found similar effects of IMD on the mRNA expression of IL-6, MCP-1, and interferon-γ in aortic walls. Aortic adventitial fibroblasts may be involved in vascular wall inflammation and remodeling in AAA by transforming into α-actin-positive myofibroblasts and producing proinflammatory cytokines, 22 which, at least in part, was modulated by oxidative stress. 8, 26 We found that IMD and antioxidant NAC both decreased the protein expression of IL-6, MCP-1, nuclear factor-κB, and tumor necrosis factor-α in adventitial fibroblasts, where proinflammatory cytokines are mainly observed in AAA according to our present and previous study. 8, 22 Pharmacological inhibition of oxidative stress has been reported to attenuate inflammation in AAA, 32, 33, 35 so the anti-inflammatory effect of IMD, at least in part, is mediated by inhibiting oxidative stress.
ROS induce apoptosis of VSMCs, which may be the soil from which AAA grow. 39 Oxidative damage to VSMCs sharply decreases the synthesis capability of elastin and collagens, thus leading to the degradation of the arterial wall and eventual rupture. 40 In our present study, IMD significantly decreased the apoptosis of VSMCs in the 2 AAA models, which was validated by staining for terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling and α-SMA. IMD decreased the protein expression of the proapoptotic proteins bax and p53 but upregulated the antiapoptotic protein bcl2. Previous studies have shown that blocking VSMC apoptosis with the antioxidant vitamin C 41 or overexpressing catalase 35 protected mice against aneurysm expansion. Consistent with these studies, our in vitro data demonstrated that IMD and antioxidant NAC both attenuated the VSMC apoptosis induced by Ang II. Thus, the antiapoptotic effect of IMD may be attributed, in part, to its inhibition of ROS generation.
ROS can specifically and reversibly react with proteins, altering their activity, localization, and half-life. Many redox signaling processes known to be affected by ROS include MAPKs. 9 Our results showed that the JNK and ERK signaling was significantly activated in the aortas of Ang II-treated mice, which is consistent with previous study, 42, 43 and this activation was abrogated by IMD. ERK has been found critical during AAA formation, and ERK antagonism can prevent AAA formation by inhibiting MMP activation. 44 Inhibition of JNK in vivo prevented the development of AAA and caused regression of established AAA. 43 Ang II can stimulate the activation of MAPK. 25 We used H 2 O 2 to induce cells to affirm the effect of IMD on inhibiting the activation of JNK and ERK signaling directly by reducing ROS generation. Both IMD and NAC could reduce H 2 O 2 -induced JNK and ERK activation, so IMD may inhibit JNK and ERK activation via its antioxidant effect.
The expression and activity of NADPH oxidase was markedly upregulated in human aneurysmal aortic tissue. 10 The NADPH oxidase is a major pathway of ROS formation in the vascular wall. 6, 45 Administration of apocynin 11 and deletion of p47phox 6 or Nox1 7 attenuated AAA formation in mouse models. In this study, our in vivo data demonstrated that IMD reduced the mRNA level of the Nox isoforms, such as p47phox, Nox2, and Nox4, and the protein expression of Nox2 and Nox4, then inhibited the activation of NADPH oxidase and ROS production. IMD and apocynin both prevented the development of AAA induced by Ang II in ApoE −/− mice. Moreover, IMD and apocynin attenuated the activation of MMPs, inflammation, and VSMC apoptosis in the aneurysm wall. Thus, IMD has a similar protective effect in AAA because apocynin protects against AAA formation. 11 In this study, apocynin treatment did not significantly decrease the incidence of AAA formation, which was inconsistent with the publication by Xiong et al 11 who reported apocynin significantly decreased the incidence of CaCl 2 -induced AAA. The discrepancy might be attributed to the use of different murine aneurysm models (different pathogenesis). Our in vitro results further demonstrated that IMD could decrease inflammation and VSMC apoptosis similar to diphenyleneiodonium. IMD may elicit its anti-inflammatory and antiapoptotic effects in AAA by inhibiting NADPH oxidase.
We found that Nox2 and Nox4 were all upregulated in AAA and may all participate in promoting AAA formation, which agrees with previous study. 4, 7, 22 Our data and that of others showed that in situ ROS generation was greatest in medial cells or adventitia fibroblasts in Ang Ⅱ-induced AAA. 8 Nox1 and Nox4 are the 2 Nox isoforms expressed in VSMCs, and Nox2 and Nox4 are the 2 Nox isoforms expressed in adventitia fibroblasts, 12 which may be responsible for the ROS generation. 9 Nox4 is the common Nox homolog that expressed in both VSMCs and adventitial fibroblasts, the cells that contribute greatly to ROS generation in vessels of AAA. Nox4 just requires binding to the smaller, membrane-bound p22phox subunit to be activated. In this study, Nox4 was significantly upregulated in the aortas of patients with AAA and Ang IIinduced AAA mice. To date, whether Nox4 is required for AAA development in vivo has not been reported, whereas these above evidence and data indicated that Nox4-derived ROS might be the major source of ROS in the pathogenesis of AAA. Our in vitro results showed that IMD silencing significantly increased Ang II-evoked ROS production, apoptosis of VSMCs, and inflammation in fibroblasts, whereas Nox4 silencing inhibited ROS generation in IMD-silenced VSMCs, then apoptosis of cells and inflammation, so the antioxidant effect of IMD was, at least in part, attributed to its inhibiting Nox4 expression. We also used siRNA Nox4 to silence Nox4 in adventitia fibroblasts; however, we found Nox4 silencing in adventitia fibroblasts did not decrease the inflammation in IMD-silenced fibroblasts (data not shown). In contrast to Nox4, that mainly generate hydrogen peroxide (H 2 O 2 ) inducing VSMC apoptosis, Nox2 seems to primarily generate superoxide (O2−), which induced proliferation of VSMCs. 9 So, we did not further explore the regulatory mechanism of Nox2 by IMD.
Enzymatic activity of Nox4 mainly depends on the expression of Nox4 and p22phox and likely does not need any further activation, 12 so we further explored the mechanism of IMD regulating the protein expression of Nox4. IMD exerts its biological effects via nonselective interaction with the CRLR/ RAMP complex, and the ligand-binding selectivity of CRLR is regulated by RAMP1, 2, and 3. 15 We found that IMD (an effective antagonist of IMD receptor), but not CGRP 8−37 (a blocking peptide of CGRP receptors) and ADM 22−52 (a blocking peptide of ADM receptors), could block the effects of IMD on Nox4 protein levels, which suggests that IMD interacted with the receptors CRLR/RAMPs to inhibit Nox4. Several signaling pathways are downstream of CRLR/RAMPs, such as cAMP/ PKA, PI3K/Akt, and MAPKs. 16 In this study, we found that H89, but not LY294002 and PD98059, could inhibit the effect of IMD on Nox4. The actions of IMD are associated with the activation of cAMP, and cAMP/PKA is the main pathway of IMD exerting its effect. The potective effects of IMD in cardiac hypertrophy 30 and vascular calcification 46 were attributed to the activation of cAMP/PKA signaling, which support our finding that the activation of cAMP/PKA may play a part in IMD downregulated Nox4 expression. The underlying molecular basis of IMD downregulated Nox4 expression should be further explored.
Numerous studies in animal models have shown significant therapeutic potential for antioxidant formulations, whereas clinical trials have failed to reveal any beneficial effects. Animal studies are critical, especially in studying the early stages of AAA, as it is nearly impossible to obtain tissue samples from small human AAA. However, some of the findings from mouse studies are hard to translate to humans because of differences in the immune system between the 2 species and the fact that the AAA develop quickly during a short-time period in the mouse models, whereas the human AAA is a chronic condition that develops during a long-time period. 47 The ineffectiveness of antioxidant trials is mainly speculated to be from poor penetrance and efficacy of antioxidants. Lack of interaction between the therapeutic antioxidant and specific ROS driving the pathological condition may also account for the inability of some antioxidant strategies. Another possible reason could be that the antioxidants are administered too late for successful intervention when extensive pathology is present. 48 So it is essential to develop technology to improve the solubility, stability, absorption of pharmacological agents, and drug delivery by precise drug release into specified targets to enhance the efficacy of antioxidants and administer early in the disease progression or as a preventative therapy. In our present study, specifically targeting NADPH oxidase-derived ROS in VSMCs, we found early administration of IMD inhibited the specific ROS generated by Nox4 in VSMCs driving the pathology of AAA. Besides, IMD can effectively elicit its biological actions via nonselective interaction with its receptors. So, IMD may exert its antioxidant effect in AAA with high efficacy and specificity.
In summary, we provide experimental evidence that the novel endogenous cardiovascular-protective peptide IMD could be a new paracrine/autocrine factor that prevents AAA by attenuating oxidative stress. The antioxidant action of IMD may be mediated by inhibiting Nox4 via activating cAMP/ PKA signaling by binding its receptor, thus protecting mice against developing the characteristic features of aneurysm, including inflammation, VSMC apoptosis, and disruption of elastin fibers. IMD might be a new therapeutic target for AAA treatment. As well, these results could promote the knowledge of the regulated effects of vascular autocrine/paracrine factors on oxidative stress.
